First evidence for the antitumor activity of nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic biliary tract cancer

被引：0
|
作者：
Hossein Taghizadeh
Matthias Unseld
Andreas Schmiderer
Angela Djanani
Klaus Wilthoner
Dieter Buchinger
Gerald W. Prager
机构：
[1] Medical University of Vienna,Clinical Division of Oncology, Department of Medicine I
[2] Comprehensive Cancer Center,Clinical Division of Gastroenterology, Hepatology and Metabolism, Department of Internal Medicine I
[3] Medical University Innsbruck,Clinical Division of Oncology, Department of Medicine I
[4] Salzkammergut Klinikum,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2020年 / 86卷
关键词：
Biliary tract cancer; Chemotherapy; Nanoliposomal irinotecan; Progression-free survival; Overall survival;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：109 / 115
页数：6
相关论文
共 50 条
  • [1] First evidence for the antitumor activity of nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic biliary tract cancer
    Taghizadeh, Hossein
    Unseld, Matthias
    Schmiderer, Andreas
    Djanani, Angela
    Wilthoner, Klaus
    Buchinger, Dieter
    Prager, Gerald W.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 86 (01) : 109 - 115
  • [2] First evidence for the antitumor activity of nanoliposomal irinotecan in metastatic biliary tract cancer
    Taghizadeh, H.
    Unseld, M.
    Schmiderer, A.
    Buchinger, D.
    Djanani, A.
    Prager, G.
    ANNALS OF ONCOLOGY, 2020, 31 : S105 - S105
  • [3] Nanoliposomal irinotecan in combination with leucovorin and 5-fluorouracil in advanced biliary tract cancers
    Allo, Gabriel
    Can, Ahu Damla
    Wahba, Roger
    Vogel, Nils
    Goeser, Tobias
    Kutting, Fabian
    Waldschmidt, Dirk
    MOLECULAR AND CLINICAL ONCOLOGY, 2022, 16 (02)
  • [4] Impact of biliary drainage for pancreatic cancer treated with nanoliposomal irinotecan, fluorouracil and folinic acid
    Nishikawa, Kazuo
    Kubotsu, Yoshihito
    Shimokawa, Mototsugu
    Otsuka, Taiga
    Shibuki, Taro
    Nakazawa, Junichi
    Arima, Shiho
    Miwa, Keisuke
    Koga, Futa
    Ueda, Yujiro
    Shimokawa, Hozumi
    Takeshita, Shigeyuki
    Hosokawa, Ayumu
    Sakai, Tatsunori
    Oda, Hisanobu
    Arita, Shuji
    Kawahira, Machiko
    Shiraawa, Tsuyoshi
    Mizuta, Toshihiko
    Mitsugi, Kenji
    ANNALS OF ONCOLOGY, 2023, 34 : S1400 - S1400
  • [5] An alternating regimen of irinotecan/5-fluorouracil/folinic acid and oxaliplatin/5-fluorouracil/folinic acid in metastatic colorectal cancer: A phase II trial
    Ferrari, V
    Valcamonico, F
    Amoroso, V
    Simoncini, E
    Vassalli, L
    Marpicati, P
    Rangoni, G
    Grisanti, S
    Pasinetti, N
    Marini, G
    ONCOLOGY, 2005, 69 (04) : 283 - 289
  • [6] Nanoliposomal irinotecan plus fluorouracil and folinic acid: a new treatment option in metastatic pancreatic cancer
    Rehman, Sana Saif Ur
    Lim, Kian
    Wang-Gillam, Andrea
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (05) : 485 - 492
  • [7] Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancer
    D Cunningham
    S Falk
    D Jackson
    British Journal of Cancer, 2002, 86 : 1677 - 1683
  • [8] Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancer
    Cunningham, D
    Falk, S
    Jackson, D
    BRITISH JOURNAL OF CANCER, 2002, 86 (11) : 1677 - 1683
  • [9] Nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy: A real-world experience
    Yu, Hung-Yuan
    Lee, Chun-Yang
    Lin, Le-Gin
    Chao, Yee
    Li, Chung-Pin
    JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2022, 85 (01) : 42 - 50
  • [10] Irinotecan combined with bolus 5-fluorouracil and folinic acid for metastatic colorectal cancer: Is this really a dangerous treatment?
    Idelevich, E
    Man, S
    Lavrenkov, K
    Gluzman, A
    Geffen, DB
    Shani, A
    JOURNAL OF CHEMOTHERAPY, 2004, 16 (05) : 487 - 490
12345